Open access
Sep 2026
Venetoclax plus hypomethylating agent improves response rates but not survival in TP53-mutated myelodysplastic syndromes
,
Michael Canonico, Parth C. Patel, N. Al Ali et al.
· Blood neoplasia · 0 citations